For adults with moderate to severe rheumatoid arthritis (RA) in whom TNF blockers did not work well.

Still have RA symptoms on a TNF blocker injection? RINVOQ (upadacitinib) versus HUMIRA® (adalimumab). Check the data. Discuss a switch.

For adults with moderate to severe rheumatoid arthritis (RA) in whom TNF blockers did not work well.

RINVOQ and HUMIRA have different FDA-approved uses and safety profiles.

It's important to talk to your doctor about all the benefits and risks of each treatment option.

Learn about the key differences between each treatment

Results from a head-to-head trial of RINVOQ vs HUMIRA
after a single TNF blocker

In this study, neither patients nor doctors knew which treatment was being given. Overall conclusions comparing two active therapies cannot be made on a single clinical trial alone.

At 12 weeks, almost twice as many people saw significant relief from joint pain, swelling, and inflammation on RINVOQ vs on HUMIRA

43% of patients taking RINVOQ achieved symptom relief versus 22% of those taking Humira; or about twice as many people on Rinvoq.

At 12 weeks, people taking RINVOQ reported an average of 43% reduction in joint pain compared to 32% taking HUMIRA*

Patients taking Rinvoq achieved 43% pain reduction from the baseline versus 32% on Humira.

RINVOQ 15 mg once daily + methotrexate (n=245)

HUMIRA 40 mg every other week + methotrexate (n=246)

*Pain levels measured on a 0-10 scale; baseline average was 7.4. At 12 weeks, mean reported pain levels were 4.2 for RINVOQ and 5.0 for HUMIRA.

RINVOQ’s safety profile was consistent with previous studies, and no new safety signals were observed. This study was not designed to make comparisons about safety. See full Important Safety Information below

What theResultssay

This study showed that switching to RINVOQ (vs HUMIRA) after trying 1 TNF blocker injection can result in better RA outcomes.

Find a rheumatologist near you to discuss your treatment options.

RINVOQ and HUMIRA have different FDA-approved uses and safety profiles

RINVOQ

Once-daily pill (15 mg)

Use

RINVOQ is a prescription medicine used to treat adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.

HUMIRA

Injection

Use

HUMIRA is a prescription medicine used alone, with methotrexate, or with certain other medicines to reduce the signs and symptoms of moderate to severe rheumatoid arthritis in adults, may prevent further damage to your bones and joints, and may help your ability to perform daily activities.

RINVOQ has a BOXED WARNING to highlight serious safety risks.
RINVOQ can cause serious side effects, including:

  • Serious infections
  • Cancer and immune system problems
  • Blood clots (thrombosis) 
  • Allergic reactions
  • Tears (perforation) in the stomach or intestines
  • Changes in certain laboratory test results
  • Increased risk of death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called Janus kinase (JAK) inhibitors. RINVOQ is a JAK inhibitor medicine.
  • Increased risk of major cardiovascular events, such as heart attack, stroke, or death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called Janus kinase (JAK) inhibitors, especially if you are a current or past smoker.

HUMIRA has a BOXED WARNING to highlight serious safety risks.
HUMIRA can cause serious side effects, including:

  • Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. Your doctor should test you for TB before starting HUMIRA, and check you closely for signs and symptoms of TB during treatment with HUMIRA, even if your TB test was negative. If your doctor feels you are at risk, you may be treated with medicine for TB.
  • Cancer. For children and adults taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. There have been cases of unusual cancers in children, teenagers, and young adults using TNF blockers. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers including HUMIRA, your chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated; tell your doctor if you have a bump or open sore that doesn't heal.

These are not all the side effects associated with either product. It's important to talk to your doctor about all the benefits and risks of each treatment option.

To understand more about the differences between each product’s safety profiles, please see full Important Safety Information for RINVOQ below     and full Patient Information for HUMIRA here

“My first TNF blocker just wasn’t working for me.
So, I had a conversation with my rheumatologist, and he said, ‘Let’s try RINVOQ.’”

Stacey,

RINVOQ patient

RINVOQ is a JAK inhibitor.

NEXT PAGE